Left Ventricular Assist Device Therapy in Advanced Heart Failure: Patient Selection and Outcomes
Key result
Left ventricular assist device (LVAD) therapy in advanced heart failure yields 1- and 2-year survival rates of 80% and 70%, respectively, justifying its use despite manageable complications.
Why the study?
Does LVAD therapy improve outcomes in patients with advanced heart failure?
Population
Patients with advanced heart failure
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
LVAD survival data may inform advanced HF decisions; leaves open optimal timing and selection pending randomized trials.
Key Points
- This review aims to summarize the patient selection criteria and outcomes associated with LVAD therapy in advanced heart failure.
- Review of factors influencing LVAD implantation decisions, including age, co-morbidities, and cardiac pathophysiology.
- Analysis of survival rates post-LVAD implantation, comparing outcomes based on patient stability.
- Discussion of common complications and their management within LVAD therapy.
- 1-year survival rate after LVAD implantation is reported at 80%.
- 2-year survival rate after LVAD implantation is reported at 70%.
- Early referral for LVAD implantation leads to superior outcomes compared to delayed intervention.
Structured PICO
Does LVAD therapy improve outcomes in patients with advanced heart failure?
P
Population
Patients with advanced heart failure
I
Intervention
Left ventricular assist device (LVAD) therapy (continuous flow devices)
O
Outcome
Survival and complications
LVAD therapy provides significant survival benefits for advanced heart failure patients, particularly when implanted early before severe decompensation occurs.
Limitations
- Complications with LVAD therapy are not uncommon
Cite This Study
Gustafsson et al. (2017) conducted a review in Advanced heart failure. Left ventricular assist device (LVAD) was evaluated. Left ventricular assist device (LVAD) therapy in advanced heart failure yields 1- and 2-year survival rates of 80% and 70%, respectively, justifying its use despite manageable complications.